Whistleblower offers window into HHS’s flawed COVID-19 response
Send a link to a friend
[May 08, 2020]
By Aram Roston and Marisa Taylor
WASHINGTON (Reuters) - A new whistleblower
complaint has drawn attention for its allegations that the Trump
administration retaliated against a scientist who sent early coronavirus
warnings. The case also provides an insider account of the dysfunction
critics say paralyzed the Department of Health and Human Services at the
dawn of the COVID-19 response.
The complaint by Dr. Rick Bright, who headed a federal agency called the
Biomedical Advanced Research and Development Authority, or BARDA, until
April 20, says HHS Secretary Alex Azar and his top aides dismissed
experts’ warnings about the impending epidemic, failed to implement
vital procedures and got sidetracked with political backbiting.
Bright’s complaint, filed Tuesday, was the subject of media reports for
its description of the administration's scramble to make malaria drugs
available at President Trump’s behest. However, the complaint also
offers fresh details that haven’t been highlighted. They show how
tensions between public health agencies likely delayed a more aggressive
early government response.
When Bright pushed top management in late January to move aggressively,
the complaint said, HHS leaders “responded with surprise at Dr. Bright’s
dire predictions and urgency, and asserted that the United States would
be able to contain the virus and keep it out of the United States.”
As Reuters reported last month, Azar in January tapped a 37-year-old
political appointee with minimal public health or administrative
experience to coordinate the agency's day-to-day response to COVID-19.
For six years before joining the Trump Administration, the aide, Brian
Harrison, had been a professional labradoodle breeder.
To read the earlier Reuters report, click https://reut.rs/2VtT2aA
The whistleblower complaint asserts Harrison and Deputy Chief of Staff
Judy Stecker blocked Bright, the government’s top vaccine expert, from
key HHS meetings in January. “The decision to eliminate BARDA was made
by Brian Harrison, Secretary Azar’s Chief of Staff, and Ms. Stecker,”
the complaint said.
BARDA and Stecker referred calls to HHS, which declined comment. Bright,
through a spokesperson, declined to comment. The HHS declined to arrange
interviews with Azar and Harrison.
In an email to a colleague in January, Bright wondered why his group was
left out but noted that other health agencies were involved, so his was
an “obvious group to cut if shrinking the table. But we have a
significant role.”
In his whistleblower complaint, he said it became clear to him why he
was pushed aside. “It was obvious that Dr. Bright’s persistent demands
for urgent action to respond to the pandemic had caused a ‘shit storm’
and a ‘commotion’ and were unwelcome in the office of the HHS
Secretary,” he wrote. “As a result, HHS leadership excluded Dr. Bright
and BARDA from these recurring meetings and from the critical
discussions about addressing the COVID-19 pandemic.”
As Reuters earlier reported, three government sources said Harrison had
also blocked the Food and Drug Administration commissioner, Stephen
Hahn, from a White House task force set up in January to address the
public health crisis.
[to top of second column]
|
Three sources say Harrison, who held previous government posts
before owning the dog breeding business, kept a “white noise”
machine outside his office door to prevent others from hearing his
conversations. The agency earlier told Reuters the device was
installed by the HHS Office of National Security. HHS also said
Harrison was not the person who initially excluded the FDA
commissioner, without saying who did.
Azar earlier told Reuters Harrison has a “deep appreciation for
HHS’s complex work.” Others say a chief of staff does not
necessarily need healthcare expertise. “There are two important
things about chiefs of staff,” said former HHS official William
Pierce. “One, you trust them and, two, they make the trains run on
time.”
DELAYED DISASTER PLAN
In his complaint, Bright also asserts the federal government didn’t
initiate a key disaster procedure until the fourth week of January.
The Disaster Leadership Group brought together management of key
agencies. When he suggested implementing the group earlier, on
January 18, Bright said his supervisor, Robert Kadlec, first said it
wasn’t necessary and then that there wasn’t “urgency.” Kadlec
referred questions to the HHS, which declined comment.
The complaint also recounts a frustrating attempt to get samples of
the actual virus from China, which Bright says “were critical to
begin development of vaccines, diagnostics, and medicines.” He said
he pushed HHS officials on January 10, 21 and 23 “to obtain
sequencing and virus samples from China, to no avail.” On January
27, as Azar was scheduled to talk with China’s health minister,
Bright unsuccessfully pressed again.
The complaint said his team “feverishly emailed health officials and
laboratories in Australia, Thailand, the United Kingdom and France
to try to obtain samples because the CDC had refused to provide
information or virus samples to them.” The Centers for Disease
Control and Prevention referred questions to HHS, which had no
comment.
Bright, whose lawyers filed the complaint with the U.S. Office of
Special Counsel, is expected to testify about his allegations next
week to Congress.
(Reporting by Aram Roston and Marisa Taylor in Washington. Editing
by Ronnie Greene.)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |